ALTSTATION.IO

Revvity, Inc. (RVTY) Stock Analysis

By Nova Skye | AltStation.io | Updated February 07, 2026

Price

$101.75

Change

+2.24%

Market Cap

$11.81B

Avg Volume

1.5M

Company Overview

Revvity, Inc. specializes in health sciences solutions, offering a broad range of products and services in the diagnostics and research space. Based in Waltham, Massachusetts, the company sells instruments, reagents, informatics, and software for detecting genetic disorders and infectious diseases. Their clientele includes pharmaceutical and biotechnology firms, laboratories, academic institutions, public health agencies, and private healthcare organizations. Revvity’s focus on early detection and genomic workflows makes its offerings essential for screening genetic abnormalities and for applications in oncology and drug discovery.

In terms of competitive positioning, Revvity is a solid challenger in the healthcare diagnostics market. Their comprehensive portfolio gives them an edge in meeting diverse customer needs, from genetic testing to immunodiagnostics. However, they face competition from larger players like Roche and Abbott, which have extensive resources and established market presence. The ongoing shift towards personalized medicine and advanced genomic solutions presents both opportunities and threats, as adaptability becomes crucial for maintaining market relevance.

Currently, Revvity appears to be in a growth phase following its rebranding from PerkinElmer, which took place in April 2023. The change signifies a strategic pivot in focus towards innovative health sciences solutions. Recent developments indicate an investment in expanding their offerings and enhancing their technology stack to keep pace with competition. Overall, Revvity is positioning itself to capitalize on the increasing demand for advanced diagnostics in a rapidly evolving healthcare landscape.

Key Financials

Market Cap

$11.81B

Revenue

$2.86B

EBITDA

$843.20M

Gross Margin

54.8%

Profit Margin

8.4%

Revenue Growth

5.9%

Total Cash

$919.86M

Total Debt

$3.37B

Free Cash Flow

$554.73M

52-Week Price Performance Analysis

Price Statistics

P/E Ratio

49.39

Forward P/E

16.96

Beta

1.09

52-Week High

$120.39

52-Week Low

$81.36

EPS

$2.06

50-Day Avg

$103.96

200-Day Avg

$95.22

Price/Book

1.59

Technical Analysis

Over the past 52 weeks, Revvity, Inc. (RVTY) has exhibited a generally bearish trend, characterized by a significant decline from its peak around $120 in February to the current price of $101.75, reflecting an 11.3% decrease. Key resistance is identified at $120, while support appears to form around $95, indicating a potential floor for price action. Notably, the chart reveals a series of lower highs and lower lows, reinforcing the bearish sentiment throughout much of the last year. In recent weeks, there has been a slight recovery from a low of approximately $95, suggesting a potential shift in momentum, although the trend remains cautious with the price still below the 50-day moving average. Currently, at $101.75, the stock is positioned well within its 52-week range, indicating the need for a substantial breakout above $105 to regain bullish momentum.

Recent News and Developments

Here’s a summary of the latest news and developments for Revvity, Inc

(RVTY) stock from the past week, covering January 31, 2026, to February 7, 2026:

1. Revvity Beats Q4 2025 Earnings and Revenue Estimates, Stock Dips on Cautious 2026 Outlook

Revvity (RVTY) announced strong fourth-quarter and full-year 2025 financial results on Monday, February 2, 2026. The company reported adjusted earnings per share (EPS) of $1.70, surpassing the consensus estimate of $1.55, and revenues of $772.06 million, slightly beating the expected $758.53 million. Despite these positive results, the stock experienced a pre-market decline of 7.89% and closed down 5.07% on the day, trading at $103.28, as investors reacted cautiously to mixed operating performance, near-term margin concerns, and the company’s 2026 outlook.

2. Revvity Issues FY 2026 Guidance Above Analyst Expectations

Alongside its Q4 2025 earnings, Revvity provided its financial guidance for fiscal year 2026. The company forecasts adjusted profit per share in the range of $5.35 to $5.45, exceeding analysts’ estimates of $5.32. Additionally, Revvity projects annual sales between $2.96 billion and $2.99 billion, also surpassing the consensus estimate of $2.93 billion. This outlook assumes continued stabilization in end-market trends, with potential upside if demand further improves.

Market Sentiment and Analyst Recommendations

Bull Case

Revvity beat Q4 earnings by 9.7% on EPS ($1.70 vs $1.55 consensus) and is guiding 2026 revenue to $2.96-2.99B, which exceeds analyst estimates of $2.93B. The ACD Labs acquisition adds $20M+ in revenue and 75 basis points of growth immediately, while the Signals Synthetica AI platform launch positions the company in high-demand pharmaceutical R&D automation. With 16 analysts rating the stock a buy and a consensus target of $119.56, there’s 17.5% upside from current levels if the company executes on guidance. The 5.9% revenue growth is solid for a $11.81B market cap player in life sciences, and the $919.86M cash position provides flexibility for continued M&A. At a P/E of 49.39, the valuation is steep, but justified if 2026 guidance holds and AI adoption accelerates in their end markets.

Bear Case

The stock dropped 5.07% immediately after beating earnings, which tells you the market doesn’t trust the narrative. Revenue growth of 5.9% is pedestrian for a company trading at 49x earnings, and the 2026 guidance assumes “continued stabilization in end-market trends”—code for no major acceleration expected. The company carries $3.37B in debt against $919.86M in cash, leaving a net debt position of $2.45B that limits financial flexibility if growth disappoints. The 52-week chart shows lower highs and lower lows with the stock still below its 50-day moving average, suggesting institutional sellers haven’t finished exiting. Margin concerns flagged in earnings and analyst commentary indicate pricing power is weak. At current levels, you’re paying peak valuations for a company guiding low-single-digit organic growth.

What to Watch

Monitor Q1 2026 results in late April for evidence that ACD Labs integration is delivering the promised $20M+ revenue contribution and that the AI platform is gaining real traction with customers. Watch for the stock to break above $105 on volume—this is the technical threshold that would signal a genuine shift from the bearish trend and validate the bull case. Track gross margin trends closely, as the company flagged near-term margin concerns; if adjusted operating margins expand in 2026, it validates the growth thesis and justifies the P/E multiple. Keep tabs on pharmaceutical R&D spending cycles and end-market demand signals, particularly in biopharma and contract research organizations, since any slowdown would make the 5.9% growth look optimistic. Finally, watch for analyst upgrades or downgrades following earnings; the current “Hold” consensus suggests skepticism, and any material upgrade would likely drive a re-rating higher.

Analyst Consensus

BUY

Based on 16 analyst opinions

Low Target

$105.00

Mean Target

$119.56

High Target

$140.00

Earnings and Financial Data

Sector

Healthcare

Industry

Diagnostics & Research

Employees

11,000

Earnings & Dividends

Next Earnings

Apr 27, 2026

EPS (Trailing)

$2.06

Dividend Yield

28.0%

Payout Ratio

13.6%

Frequently Asked Questions

Is RVTY a good stock to buy?

Yes, analysts recommend a buy with a target price of $119.56. It currently trades at $101.75, presenting a potential upside of around 17.5%.

What is RVTY’s price target?

The current analyst price target for Revvity, Inc. (RVTY) is $119.56. This projection supports the bullish outlook based on growth potential in the healthcare diagnostics sector.

Does RVTY pay a dividend?

Yes, RVTY offers a dividend yield of 28.0%. This high yield is attractive for income-focused investors.

What is RVTY’s earnings ratio?

RVTY has a P/E ratio of 49.39 and a forward P/E of 16.96. The forward P/E indicates that earnings growth is expected, making it a compelling option for growth investors.

What has been RVTY’s stock performance over the past year?

RVTY’s 52-week range is $81.36 to $120.39. Trading near $101.75 suggests it has shown resilience, maintaining a solid position within its historical range.

Related Stock Reports

Disclaimer: This report is for informational purposes only and does not constitute financial advice. The analysis and opinions expressed are those of AltStation.io and should not be relied upon as the sole basis for investment decisions. Always conduct your own research and consult with a qualified financial advisor before making investment decisions. Past performance does not guarantee future results. Updated February 07, 2026.